Filtered By:
Specialty: Endocrinology
Condition: Heart Failure
Education: Study
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 271 results found since Jan 2013.
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Abstract
Sodium glucose cotransporter 2 (SGLT2) inhibitors have a unique mechanism of action leading to excretion of glucose in the urine and subsequent lowering of plasma glucose. This mechanism is independent of β-cell function; thus, these agents are effective treatment for type 2 diabetes mellitus (T2DM) at theoretically any disease stage. This class should not confer an additional risk of hypoglycemia (unless combined with insulin or an insulin secretagogue) and has the potential to be combined with other classes of glucose-lowering agents. Empagliflozin is one of three currently approved SGLT2 inhibitors in...
Source: Current Diabetes Reviews - June 12, 2016 Category: Endocrinology Authors: Levine MJ Tags: Curr Diabetes Rev Source Type: research
Cardiovascular safety of glucose ‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
ConclusionsThis nationwide observational study showed that second‐line treatment with TZD and DPP‐4 inhibitor as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - July 18, 2016 Category: Endocrinology Authors: Nils Ekstr öm, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research
Circulating fibroblast growth factor ‐23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease
ConclusionsFGF‐23 plasma levels predict adverse cardiovascular outcomes in coronary artery disease patients who have T2D but not in those without T2D. This finding should be confirmed in larger studies. Copyright © 2016 John Wiley & Sons, Ltd.
Source: Diabetes/Metabolism Research and Reviews - April 24, 2016 Category: Endocrinology Authors: Jos é Tuñón, Beatriz Fernández‐Fernández, Rocío Carda, Ana M. Pello, Carmen Cristóbal, Nieves Tarín, Álvaro Aceña, María Luisa González‐Casaus, Ana Huelmos, Joaquín Alonso, Óscar Lorenzo, Emilio González‐Parra, Ignacio Hernández‐Go Tags: Research Article Source Type: research
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study
The aim was to assess whether the use of additional data from the Disease Management Program (DMP) diabetes mellitus type 2 to minimize the potential for residual confounding will alter the estimated risk of either myocardial infarction, ischemic stroke or heart failure in patients with type 2 diabetes using sulfonylureas compared to dipeptidyl peptidase-4 (DPP-4) inhibitors in addition to metformin based on routine health care data.
Source: Journal of Diabetes and Its Complications - May 18, 2016 Category: Endocrinology Authors: Dirk Enders, Bianca Kollhorst, Susanne Engel, Roland Linder, Frank Verheyen, Iris Pigeot Source Type: research
Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
We examined whether the incidence of cardiovascular disease in Look AHEAD varied by changes in weight or fitness. Methods Look AHEAD was a randomised clinical trial done at 16 clinical sites in the USA, recruiting patients from Aug 22, 2001, to April 30, 2004. In the trial, 5145 overweight or obese adults aged 45–76 years with type 2 diabetes were assigned (1:1) to an intensive lifestyle intervention or diabetes support and education. In this observational, post-hoc analysis, we examined the association of magnitude of weight loss and fitness change over the first year with incidence of cardiovascular disease. The primar...
Source: The Lancet Diabetes and Endocrinology - August 30, 2016 Category: Endocrinology Source Type: research
Is vitamin E supplementation effective in reducing mortality related to cardiovascular events in people with type 2 diabetes mellitus? A systematic review
Conclusions Although, two studies showed no benefit from vitamin E supplementation, the remaining studies demonstrated that vitamin E supplementation provided cardiovascular benefits in a specific diabetic subpopulation. The study population that derived a favorable outcome from vitamin E supplementation consisted of diabetic patients with the Hp 2–2 genotype. Hence, further studies should be conducted in diabetic populations with the Hp 2–2 genotype for identifying the definitive effects of vitamin E.
Source: IJC Metabolic and Endocrine - September 12, 2016 Category: Endocrinology Source Type: research
Insulinlike growth factor binding protein-1 and ghrelin predict health outcomes among older adults: CHS cohort.
CONCLUSIONS: Circulating IGFBP-1 and ghrelin measured during an OGTT predict major health events and death in older adults, which may explain the influence of the GH-IGF-axis on lifespan and health.
PMID: 27820656 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - November 6, 2016 Category: Endocrinology Authors: Kaplan RC, Strizich G, Aneke-Nash C, Dominguez-Islas C, Bůžková P, Strickler H, Rohan T, Pollak M, Kuller L, Kizer JR, Cappola A, Li CI, Psaty BM, Newman A Tags: J Clin Endocrinol Metab Source Type: research
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
AbstractEmpagliflozin is an oral treatment for type 2 diabetes mellitus (T2DM), one of the leading causes of death in the US and around the world. Recently, the EMPA-REG OUTCOME study has shown that empagliflozin added to standard of care treatment reduced the risk of cardiovascular (CV) events in patients with T2DM who were also at increased CV risk. The risk of major adverse CV events (MACE: first occurrence of CV death, non-fatal myocardial infarction, or non-fatal stroke) was reduced by 14% relative to placebo (HR 0.86; 95.02% CI: 0.74 –0.99;P = 0.04 for superiority). The risk of CV death was reduced by 38% relativ...
Source: Diabetes Therapy - November 10, 2016 Category: Endocrinology Source Type: research
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes
CONCLUSIONS
Absent dorsalis pedis and/or posterior tibial pulses are independent predictors of major vascular outcomes in patients with type 2 diabetes. These simple clinical indicators should be used to improve risk stratification and treatment of these patients.
Source: Diabetes Care - November 21, 2016 Category: Endocrinology Authors: Mohammedi, K.; Woodward, M.; Zoungas, S.; Li, Q.; Harrap, S.; Patel, A.; Marre, M.; Chalmers, J.; on behalf of the ADVANCE Collaborative Group Tags: Pathophysiology/Complications Source Type: research
Baseline Adiponectin Concentration and Clinical Outcomes among Patients with Diabetes and Recent Acute Coronary Syndrome in the EXAMINE Trial
ConclusionsIn this contemporary population of patients with diabetes and ACS, adiponectin concentration was independently associated with increased risk of CV death, all‐cause mortality, and HF hospitalization. The relationship between adiponectin and CV outcomes is complex and deserves further study.
Source: Diabetes, Obesity and Metabolism - January 31, 2017 Category: Endocrinology Authors: Brian A. Bergmark, Christopher P. Cannon, William B. White, Petr Jarolim, Yuyin Liu, Marc P. Bonaca, Faiez Zannad, David A. Morrow Tags: ORIGINAL ARTICLE Source Type: research
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
CONCLUSIONS
Among older patients with well-controlled type 2 diabetes and cardiovascular disease, sitagliptin had neutral effects on cardiovascular risk and raised no significant safety concerns.
Source: Diabetes Care - March 20, 2017 Category: Endocrinology Authors: Bethel, M. A.; Engel, S. S.; Green, J. B.; Huang, Z.; Josse, R. G.; Kaufman, K. D.; Standl, E.; Suryawanshi, S.; Van de Werf, F.; McGuire, D. K.; Peterson, E. D.; Holman, R. R.; for the TECOS Study Group Tags: Emerging Science and Concepts for Management of Diabetes and Aging Source Type: research
Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People.
Conclusion: The ORIGIN biomarkers predicted CV outcomes in the independent HOPE cohort. Adding hsTnI levels to the previously identified models in ORIGIN modestly improved their performance.
PMID: 28368516 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - March 24, 2017 Category: Endocrinology Authors: Gerstein HC, Paré G, McQueen MJ, Lee SF, Hess S, ORIGIN Trial Investigators Tags: J Clin Endocrinol Metab Source Type: research
Anti- hyperglycemic agents for the treatment of type 2 diabetes mellitus: Role in cardioprotection during the last decade.
Abstract
Type 2 diabetic patients are known to have a tendency to develop cardiovascular (CV) disease (CVD), and related unfavourable outcomes such as heart failure, myocardial infarction (MI), cerebrovascular events (eg. stroke), and related mortality. Long- term clinical trials have revealed contradictory findings regarding the relationship between glycemic control and CV benefits due to variations in the key characteristics of the study population. During the last decade, number of pharmacological agents used for glucose- lowering in the treatment of type 2 diabetes mellitus (T2DM) has increased owing to the in...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - April 23, 2017 Category: Endocrinology Authors: Kocyigit D, Gurses KM, Yalcin MU, Tokgozoglu L Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Blood pressure circadian rhythms and adverse outcomes in type 2 diabetics diagnosed with orthostatic hypotension
ConclusionsIn subjects who had type 2 diabetics diagnosed with OH, the BP circadian rhythm usually showed riser patterns, and they had increased rates of mortality and major adverse cardiac and cerebrovascular events.This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - May 11, 2017 Category: Endocrinology Authors: Jing Chang, Yuan ‐Ping Hou, Jin‐Ling Wu, Xiang‐Yang Fang, Sheng‐Li Li, Miao‐Bing Liu, Qian‐Mei Sun Tags: Original Article Source Type: research
Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study
CONCLUSIONS
The presence of major ECG abnormalities is associated with an increased risk of CVD in patients with type 1 diabetes. This suggests a potential role for ECG screening in patients with type 1 diabetes to identify individuals at risk for CVD.
Source: Diabetes Care - May 22, 2017 Category: Endocrinology Authors: Soliman, E. Z.; Backlund, J.-Y. C.; Bebu, I.; Orchard, T. J.; Zinman, B.; Lachin, J. M.; the DCCT/EDIC Research Group Tags: Cardiovascular and Metabolic Risk Source Type: research
